SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Burke LB, Kennedy DL, Miskala PH, Papadopoulos EF, Trentacosti AM. The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval. Clin Pharmacol Ther. 2008;84:281-283.
  • 2
    Wagner LI, Wenzel L, Shaw E, Cella D. Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions. J Clin Oncol. 2007;25:5058-5062.
  • 3
    Sprangers MAG. Disregarding clinical trial-based patient-reported-outcomes is unwarranted: 5 advances to substantiate the scientific stringency of quality-of life instrument. Acta Oncol. 2010;49:155-163.
  • 4
    Quinten C, Maringwa J, Gotay C, et al. Can patient self-reporting of symptoms complement clinician ratings in estimating cancer survival? J Natl Cancer Inst. 2011;103:1851-1858.
  • 5
    Basch E, Xiaoyu J, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101:1624-1632.
  • 6
    Bottomley A, Coens C, Suciu S, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2009;27:2916-2923.
  • 7
    Taphoorn MJ, Stupp R, Coens C, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:937-944.
  • 8
    Sprangers MAG, Schwartz CE. Integrating response shift into health-related quality of-life research: a theoretical model. Soc Science Med. 1999;48:1507-1505.
  • 9
    US Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labelling Claims. Rockville, MD: US Food and Drug Administration; 2006.
  • 10
    Collette L, Van Andel G, Bottomley A, et al. Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of 3 studies of the European Organization for Research and Treatment of Cancer Genito-Urinary Group. J Clin Oncol. 2004;22:3877-3885.
  • 11
    Sloan JA, Zhao X, Novotny PJ, et al. Relationship between deficits in overall quality of life and non-small-cell lung cancer survival. J Clin Oncol. 2012;30:1498-1504.
  • 12
    Chau I, Norman AR, Cunningham D, Waters J, Oates J, Ross J. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer: pooled analysis from 3 multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22:2395-2403.
  • 13
    Tan AD, Novotny PJ, Kaur JS, et al. A patient-level meta-analytic investigation of the prognostic significance of baseline quality of life (QOL) for overall survival (OS) among 3,704 patients participating in 24 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials [abstract]. J Clin Oncol. 2007;26(suppl). Abstract 9515.
  • 14
    Gotay CC, Kawamoto T, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26:1355-1363.
  • 15
    Mauer M, Bottomley A, Coens C, Gotay C. Prognostic factor analysis of health-related quality of life data in cancer: a statistical methodological evaluation. Expert Rev Pharmacoecon Outcomes Res. 2008;8:179-196.
  • 16
    Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009;10:865-871.
  • 17
    Aaronson N, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
  • 18
    Fayers P, Aaronson N, Bjordal K, Curran D. Groenveld M. EORTC QLQ-C30 Scoring Manual. 2nd ed. Brussels, Belgium: EORTC Quality of Life Study Group; 2001.
  • 19
    Bjordal K, de Graeff A, Fayers PM, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (the EORTC QLQ-H&N35). Eur J Cancer. 2000;36:213-219.
  • 20
    Osoba D, Aaronson NK, Zee B, et al. Modification of the EORTC QLQ-C30 (version 2.0) based upon content validity and reliability testing in large samples of patients with cancer. Qual Life Res. 1997;6:103-108.
  • 21
    Efficace F, Bottomley A, Coens C, et al. Does a patient's self-reported health related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? Eur J Cancer. 2006;42:42-49.
  • 22
    Fossa SD, Paus E, Lindegaard M, Newling DW. Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment. Br J Urol. 1992;69:175-179.
  • 23
    Kramer JA, Curran D, Piccart M, et al. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer. 2000;36:1498-1506.
  • 24
    Higgens JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
  • 25
    Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
  • 26
    Maoine P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian Lung Cancer in the Elderly study. J Clin Oncol. 2005;23:6865-6872.
  • 27
    Braun DP, Gupta D, Staren ED. Quality of life assessment as a predictor of survival in non-small cell lung cancer [serial online]. BMC Cancer. 2011;11:353.
  • 28
    Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407-415.
  • 29
    Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139-144.
  • 30
    Curran C, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol. 2007;25:2191-2197.
  • 31
    Maisey NR, Norman A, Watson M, et al. Baseline quality of life predicts survival in patients with advances colorectal cancer. Eur J Cancer. 2002;38:1351-1357.
  • 32
    Fielding R, Wong WS. Quality of life as a predictor of cancer survival among Chinese live and lung cancer patients. Eur J Cancer. 2007;43:1723-1730.
  • 33
    Eton DT, Fairclough DJ, Cella D, Yount SE, Bonomi P, Johnson DH. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group study 5592. J Clin Oncol. 2003;21:1536-1543.
  • 34
    Van Heijl M, Sprangers MAG, de Boer AGEM, et al. Preoperative and early postoperative quality of life predict survival in potentially curable patients with oesophageal cancer. Ann Surg Oncol. 2010;17:23-30.
  • 35
    Blazeby JM, Brookes ST, Alderson D. The prognostic value of quality of life scores during treatment for oesophageal cancer. Gut. 2001;49:227-230.
  • 36
    Bergquist H, Johnsson A, Hammerlid E, Wenger U, Lundell L, Ruth M. Factors predicting survival in patients with advanced oesophageal cancer: a prospective multicentre evaluation. Aliment Pharmacol Ther. 2008;27:385-395.
  • 37
    Efficace F, Therasse P, Piccart MJ, et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. J Clin Oncol. 2004;22:3381-3388.
  • 38
    Coates A, Hurny C, Peterson HF, et al. Quality of life scores predict outcome in metastatic but not early breast cancer: International Breast Cancer Study Group. J Clin Oncol. 2000;18:3768-3774.
  • 39
    Mauer M, Stupp R, Taphoorn MJB, et al. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncoiogy Groups, and NCIC Clinical Trials Group study. Br J Cancer. 2007;97:302-307.
  • 40
    Klein M, Postma TJ, Taphoorn MJ, et al. The prognostic value of cognitive functioning in the survival of patients with high-grade glioma. Neurology. 2003;61:1796-1798.
  • 41
    Dancey J, Zee B, Osoba D, et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy—the National Cancer Institute of Canada Clinical Trials Group. Qual Life Res. 1997;6:151-158.
  • 42
    Fang FM, Tsai WL, Chiu HC, Kuo WR, Hsiung CY. Quality of life as a survival predictor for oesophageal squamous cell carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2004;58:1394-1404.
  • 43
    Hofso K, Miaskowski C, Bjordal K, Cooper BA, Rustoen T. Previous chemotherapy influences the symptom experience and quality of life of women with breast cancer prior to radiation therapy. Cancer Nurs. 2012;35:167-177.
  • 44
    Lemieux J, Goodwin PJ, Bordeleau LJ, et al. Quality-of-life measurements in randomized clinical trials in breast cancer: an updated systematic review (2001-2009). J Natl Cancer Inst. 2011;103:178-231.
  • 45
    Lipscomb J, Gotay C, Snyder C. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J Clin. 2007;57:278-300.
  • 46
    Movsas B, Moughan J, Sarna L, et al. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol. 2009;27:5816-5822.
  • 47
    Claassens L, van Meerbeeck J, Coens C, et al. Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodological issues in randomized controlled trials. J Clin Oncol. 2011;29:2104-2120.
  • 48
    Sloan JA, Berk L, Roscoe J, et al. Integrating patient-reported outcomes into cancer symptom burden management clinical trials supported by the National Cancer Institute-sponsored clinical trial networks. J Clin Oncol. 2007;25:5070-5077.
  • 49
    National Cancer Institute. Patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Available from http://outcomes.cancer.gov/tools/pro-ctcae.html. Assessed September 18, 2013.